Y-mAbs Therapeutics (YMAB) Misses Q1 EPS by 13c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.15), $0.13 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $20.25 million versus the consensus estimate of $15.72 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM